- Trump secretly sent Covid tests to Putin: Bob Woodward book
- Neural networks, machine learning? Nobel-winning AI science explained
- Boeing delivers 27 MAX jets in September despite strike
- Stock markets diverge as Hong Kong sinks, oil prices fall
- US trade gap narrowest in five months as imports slip
- Stay and 'you are going to die': Florida braces for next hurricane
- Geoffrey Hinton, soft-spoken godfather of AI
- Duo wins Physics Nobel for 'foundational' AI breakthroughs
- German 'Maddie' suspect could be free in 2025 after cleared of separate sex crimes
- China slaps provisional tariffs on EU brandy imports
- Duo wins Physics Nobel for key breakthroughs in AI
- German 'Maddie' suspect could be free soon after cleared of separate sex crimes
- China says to take anti-dumping measures against EU brandy imports
- China stocks rally fizzles on stimulus worries amid Asia retreat
- China stocks rally peters out on stimulus worries amid Asia retreat
- Taiwan's Foxconn says building world's largest 'superchip' plant
- Nobel literature jury may go for non-Western writer
- From Bolivia to Indonesia, deforestation continues apace
- China holds off on fresh stimulus but 'confident' will hit growth target
- German suspect in 'Maddie' case faces verdict in sex crimes trial
- Top economic official 'confident' China will hit 2024 growth target
- COP29 fight looms over climate funds for developing world
- Shanghai stocks soar to extend stimulus rally amid Asia-wide drop
- Will Tesla's robotaxi reveal live up to hype?
- 'Invisibility' and quantum computing tipped for physics Nobel
- Oil prices extend gains on Mideast tensions, Wall Street falls
- 'Dark day': Victims mourned around the globe on Oct. 7 anniversary
- Mission to probe smashed asteroid launches despite hurricane
- Oil prices extend gains on Mideast tensions, Wall Street slips
- Europe's asteroid mission Hera launches despite hurricane
- Oil prices extend gains on Mideast tensions, Wall Street retreats
- What is microRNA? Nobel-winning discovery explained
- Weather may delay launch of mission to study deflected asteroid
- China to flesh out economic stimulus plans after bumper rally
- Asian markets track Wall St rally on US jobs data
- World marks anniversary of Oct. 7 attack on Israel
- Asian markets track Wall St rally on jobs data
- Cancer, cardiovascular drugs tipped for Nobel as prize week opens
- Tunisia incumbent Saied set to win presidential vote: exit polls
- 'Difficult day': Oct 7 commemorations begin with festival memorial
- Commemorations begin for anniversary of attack on Israel
- Tunisia voting ends as Saied eyes re-election with critics behind bars
- Drowned by hurricane, remote N.Carolina towns now struggle for water
- Two elephants die in flash flooding in northern Thailand
- Tunisia votes with Saied set for re-election
- Too hot by day, Dubai's floodlit beaches are packed at night
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Italy targets climate activists in 'anti-Gandhi' demo clampdown
- US trade chief defends tariff hikes when paired with investment
- EU court blocks French ban on vegetable 'steak' labelling
RBGPF | -0.46% | 60.52 | $ | |
RYCEF | 1.29% | 6.97 | $ | |
CMSC | 0.12% | 24.6 | $ | |
AZN | -0.01% | 76.86 | $ | |
NGG | 0.55% | 65.845 | $ | |
GSK | -1.59% | 38.025 | $ | |
RIO | -4.61% | 66.555 | $ | |
BP | -3.48% | 32.025 | $ | |
BTI | 0.01% | 35.205 | $ | |
SCS | -0.35% | 12.905 | $ | |
RELX | 1.32% | 46.655 | $ | |
CMSD | 0.34% | 24.875 | $ | |
JRI | 0.06% | 13.188 | $ | |
BCC | 0.34% | 141.755 | $ | |
BCE | -0.23% | 33.452 | $ | |
VOD | -0.41% | 9.65 | $ |
US biopharma firm Amgen to acquire Horizon Therapeutics for $28 bn
US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion.
The California-based company said it will pay cash to the tune of $116.50 a share in Horizon Therapeutics, a 20 percent premium over Horizon's closing price Friday on Wall Street, in what would be the biggest deal of the year in the health sector.
The bid will be financed through a bank lending facility.
Founded in 2005, Horizon Therapeutics develops and markets drugs for rare, auto-immune and inflammatory illnesses. It is best known for making Tepezza, which is used to treat thyroid eye disease, the symptoms of which include eye pain, redness and swelling.
Amgen said the deal would strengthen its drug portfolio, while positioning Horizon's products through its global commercial and manufacturing network.
"The acquisition of Horizon is a compelling opportunity for Amgen and one that is consistent with our strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases," Amgen CEO Robert Bradway said.
The deal is subject to approval by antitrust regulators in the United States, Austria and Germany, as well as the approval of the Irish High Court. If all goes well, the deal should be concluded in the first half of 2023, Amgen said.
Shares of Horizon surged nearly 15 percent to $111.70 in mid-morning trading, while Amgen dropped 1.2 percent to $275.44.
Horizon is based in Ireland, but trades in New York.
Responding to an article in The Wall Street Journal, Horizon Therapeutics said last month it was in preliminary talks with Amgen, but also with Johnson & Johnson and French company Sanofi.
Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria."
J&J also said in early December that it had dropped its pursuit of the deal.
- 'Solid portfolio' -
The transaction shows "Big Pharma will pay top dollar for a solid portfolio and pipeline in therapeutics for rare diseases," where the competitive landscape is "generally much less crowded," said Derren Nathan, head of equity research at Hargreaves Lansdown in Britain.
"With AstraZeneca's acquisition of Alexion still fresh in the mind, the trend for consolidation is clear but the universe of large specialists in the space is dwindling, so further deals may be more bite-sized and opportunistic," Nathan added.
Sales of Tepezza came in at $491 million in the third quarter and $1.7 billion for all of 2021, more than half of Horizon's total revenues.
Other major Horizon products include Krystexxa, which treats chronic gout; Ravicti, which treats urea disorders; and Uplizna, which treats an autoimmune disease.
"In nearly 15 years, we have built one of the fastest-growing and most respected companies in the biotechnology industry from the ground up," said Horizon Chief Executive Tim Walbert.
"Amgen is aligned with that commitment and passion and will continue to maximise the value of the current portfolio and pipeline and accelerate the ability to reach more patients globally."
Amgen's portfolio also includes an autoimmune treatment, Enbrel, but sales have fallen in recent quarters.
Pharma analysts note that Amgen's revenue outlook has been clouded by upcoming patent expirations for key drugs such as Prolia, which treats osteoporosis, and Otezla, which treats psoriasis and psoriatic arthritis.
"Our focus is on long-term growth," Bradway said of the patent outlook. "We're not trying to solve for the short- or medium-term, but rather we're trying to invest capital in order to generate long-term returns for our shareholders."
"And we think this transaction is consistent with that objective."
D.Philippon--CPN